Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. (Q50328960)
Jump to navigation
Jump to search
scientific article published on 4 December 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. |
scientific article published on 4 December 2017 |
Statements
1 reference
Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. (English)
1 reference
Kei Kawaguchi
Tasuku Kiyuna
Kentaro Miyake
Masuyo Miyake
Yunfeng Li
Norio Yamamoto
Katsuhiro Hayashi
Hiroaki Kimura
Shinji Miwa
Scott D Nelson
Sarah M Dry
Arun S Singh
Irmina A Elliott
Tara A Russell
Mark A Eckardt
Fritz C Eilber
Robert M Hoffman
4 December 2017
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference